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Murine splenic cellsAbstract Background: Extracts of Echinacea have been used traditionally for the treatment of
diverse types of infections and wounds. They have become very familiar immunostimulant
herbal medicine. However, the speciﬁc immunomodulatory effect of Echinacea remains to be
elucidated.
Aim: In our study, the effect of Echinacea purpurea extract on the generation of immature DCs
from monocytes was described, as well as its effect on DC differentiation. In addition, an in vivo
experiment was conducted to investigate whether treatment of mice with extracts derived from E.
purpurea has immunomodulatory effect on murine splenic DCs.
Methods: Immature DCs were generated by incubating peripheral blood monocytes with
cytokine cocktail (GM-CSF + IL-4) and matured by tumor necrosis factor-a (TNF-a). The cells
were randomized to 5 groups to investigate E. purpurea effect in different stages. Phenotypic
analysis of cell marker CD83-expressed on DCs was performed by ﬂow cytometry. Mice were
randomly divided into 3 groups; control, E. purpurea treated and E. purpurea-TNF-a treated
group. The murine splenic DCs were isolated and phenotyped for CD83 and CD11c by ﬂow
cytometry.
Results: Treatment of monocytes with E. purpurea prior to addition of the maturation factor
TNF-a resulted in a signiﬁcant decrease in the yield of DC expressing CD83. On the other hand,
immature DCs generated in the culture in the presence of GM-CSF and IL-4, when treated
simultaneously with E. purpurea and TNF-a, exhibited an insigniﬁcant change in the yield of
CD83-expressing DCs compared with untreated control. The in vivo experiments showed that
186 N.E. El-Ashmawy et al.splenic DCs obtained from mice treated with E. purpurea with or without TNF-a did not exhibit
signiﬁcant changes in CD83 or CD11c compared with those obtained from control mice.
Conclusion: Our ﬁndings suggest that the immunomodulatory mechanisms of E. purpurea
impact generation fate of DCs rather than differentiation stages. The results obtained in the
in vivo study utilizing murine splenic DCs supported those observed in vitro.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology.1. Introduction
Immunotherapy is the treatment of a disease by producing,
improving or overcoming an immune response.
Immunotherapies, produced to obtain or augment an immune
response, are classiﬁed as immunostimulants. On the other
hand, immunotherapies prepared to reduce or suppress, are
assorted as immunosuppressants [14].
Cell based immunotherapies are shown to be useful for
some cancers. Immune effector cells such as lymphocytes,
macrophages, dendritic cells, natural killer cells (NKs) and
cytotoxic T lymphocytes (CTL), operate concurrently to guard
the body toward cancer by marking unusual antigens repre-
sented on the surface of the malignant cells due to mutation
[8].
The immunomodulating characteristics of plants are being
examined widely to achieve the desirable effects on disease
prevention. Consequently, herbal remedies have been utilized
for centuries for safety, effectiveness, minor side effect and
cultural acceptability. Therefore plant and its products are
harmless and so, there is continuous application of plant
product as an optional way to cure the patients and this
approach is in practice from the ancient times [29].
Echinacea is considered one of the most popular herbal sup-
plements used to attenuate colds, sore throats, coughs and
other respiratory infections [25]. Three of the nine species of
Echinacea possess medical uses: Echinacea angustifolia,
Echinacea pallida and Echinacea purpurea, which are the most
commonly consumed species in the United States [4].
Echinacea includes a diversity of medically essential materials
that perform a role in its therapeutic effects. They involve alky-
lamides, caffeic acid derivatives, glycoproteins, polysaccha-
rides, polyacetylenes, phenolic mixtures, cinnamic acids,
essential oils and ﬂavonoids [25].
E. purpurea has numerous advantageous characteristics,
especially activation of the immune system, by triggering the
alternating complement pathway as well as raising the number
of distributing white blood cells, stimulating phagocytosis,
T-cell production, lymphocytic activity, cytokine production,
cellular respiration and enzyme secretion [11].
Dendritic cells (DCs) are the common effective to the most
potent and professional antigen-presenting cells of the immune
system required in both enhancing immune responses and
maintaining tolerance [33]. In response to infections, DCs
advance the production of effector CD4+ T helper 1 (Th1)
and CD8+ T cell-dominated immune replies. Furthermore to
these effector responses, DCs can be directed to become tolero-
genic and increase regulatory T cells (Tregs), that control effec-
tor T cell responses, a process that is important for
preservation of immune homeostasis and control of autoim-
mune diseases and hypersensitivities [6].DCs can exist in two main states, steady state immature
dendritic cells and fully mature DCs. The difference between
immature and mature DCs is notably based on changes occur-
ring on a phenotypic level and functional level [7]. Immature
dendritic cells exhibited characteristics of primary cells, deﬁned
by expression of classical dendritic cell surface markers
CD11c, CD11b and major histocompatibility complex class
II (MHC-II). Phenotypic maturation is achieved when DCs
up-regulate surface maturation markers such as CD80,
CD83, and CD86 [16].
An important biological function of DCs relies on the con-
tinuous sampling of their tissue environment, responding to
stress, danger signals and transducing the collected molecular
information to other cell types of the immune system [20].
DCs are equipped with unique sets of phylogenetically con-
served Pattern Recognition Receptors (PRRs), which are spe-
cialized to recognize Microbe Associated Molecular Patterns
(MAMPs) and Danger Associated Molecular Patterns
(DAMPs) [28].
Activation of DCs by MAMPs and DAMPS results in the
rapid, chemokine-mediated translocation of DCs to draining
lymph nodes where they have the chance to contact antigen-
speciﬁc T-lymphocytes to initiate adaptive immune responses
[24]. This process ensures the transfer of molecular informa-
tion collected in the periphery toward other cell types of both
innate and adaptive immunity such as neutrophils, granulo-
cytes, NKs, killer T cells, T- and B-lymphocytes [2].
Because of the powerful immuno-regulatory functions of
DCs, there has been high attention in identifying the
immunomodulating drugs that manage the various features
of these cells to ﬁnally recognize means to manage the function
of DCs for the intelligent pattern of DC-based immune-
interventions. The aim of this research was to examine the
immunomodulatory effect of ethanolic extract derived from
E. purpurea on DC generation from human monocytes and
to examine its effect on DCs maturation via series of in vitro
experiments. We also studied whether treatment with extracts
derived from E. purpurea has immunomodulatory effect on
splenic murine DCs.2. Materials and methods
2.1. Materials and reagents
Dulbecco’s modiﬁed Eagle medium (DMEM) and phosphate
buffered saline-Ca2+ Mg2+ free (PBS) were obtained from
Biowhittaker, Belgium. Granulocyte macrophage-colony
stimulating factor (GM-CSF), phycoerythrin (PE) anti-
human CD83 monoclonal antibody (cat# 12-0839, clone:
HB15e), ﬂuorescence-activated cell sorting (FACS) buffer
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Austria. Phycoerythrin hamster anti-mouse CD11c mono-
clonal antibody (cat# MCA1369T, clone: N418) and ﬂuores-
cein isothiocyanate (FITC) rat anti-mouse CD83 monoclonal
antibody (cat# MCA2747F, clone: 3D11) were obtained from
AbD Serotec, USA. IL-4 was obtained from Sigma
Aldrich, USA. TNF-a was obtained from R&D Systems,
USA. Penicillin–streptomycin solution (Pen/Strep) was
obtained from Euro-lone, Europe. Amphotericin B
(Fungizone) was obtained from Gibco, USA. Biocoll sepa-
rating solution, density 1.077 g/mL, was obtained from
Biochrom, Germany. E. purpurea dried whole plant
was obtained from Haraz Co., Egypt. Heparin calcium
(Cal-heparin) 5000 U was obtained from Amoun
Pharmaceutical Co., Egypt. Human albumin (Zenalb) 20%
was obtained from Bio Products Laboratory Limited, United
Kingdom. All other chemicals and reagents were of high ana-
lytical grade.
2.2. Extraction of E. purpurea
Dried whole plant was powdered and soaked in absolute
methanol for one day. After one day, methanolic extraction
was separated by ﬁltration and evaporated using Rota Vap
instrument (Heidolph, Germany). Then, the extract contain-
ing active constituents was divided into aliquots, weighed and
stored at 20 C [23].
2.3. In vitro experiments for culture of DCs
2.3.1. Isolation of monocytes
The present study was approved by the Research Ethics
Committee of Tanta Faculty of Pharmacy. Heparinized
human peripheral blood was collected and mononuclear cells
were isolated by Biocoll density gradient centrifugation.
Peripheral blood monocytes (PBMCs) were then placed in
the incubator (Shel lab, USA) and allowed to adhere for
2 h at 37 C in 5% CO2. Non-adherent cells of peripheral
blood lymphocytes (PBLs) were gently removed [10].
2.4. Generation of human monocyte-derived DCs
DCs were generated according to Rubinstein et al. [26]. Brieﬂy,
puriﬁed human monocytes were cultured (106 cells/mL) on day
zero in DMEM medium supplemented with 100 lL ampho-
tericin B (1 lg/mL), 100 lL Pen/Strep, IL-4 (10 ng/mL) and
GM-CSF (10 ng/mL) for 9 days in order to obtain immature
DCs. The cells were further fed on day 3 with fresh DMEM
medium (half the original medium volume containing the same
concentration of cytokine cocktail). Maturation was achieved
by addition of TNF-a (10 ng/mL) dissolved in PBS on day 7
and kept for 48 h. Mature DCs were harvested and analyzed
on day 9 [34].
2.5. Cell culture grouping
Regarding the above mentioned preparation of DCs, the cells
were randomized to 5 groups to investigate E. purpurea effect
at different stages: Group A, control immature DCs; Group B,
E. purpurea added on day 7; Group C, TNF-a (10 ng/mL)added on day 7 + E. purpurea on day 8; Group D, E. purpurea
added on day 7 + TNF-a (10 ng/mL) on day 8; and Group E,
E. purpurea added on day 0 + TNF-a (10 ng/mL) on day 7.
The prepared concentrated extract of E. purpurea was diluted
in absolute ethanol to prepare 500 lg/mL solution. 0.5% of
E. purpurea ethanolic solution, equivalent to 25 lg concen-
trated E. purpurea extract, was added to the cell culture on
the time speciﬁed for each group [4]. Morphological changes
of cells were examined on days 0, 7, and 9 using inverted
microscope Carl Zeiss, Germany.
2.6. Flow cytometry analysis for CD83 expression in DCs
Approximately 106 cells were harvested and stained with anti-
CD83-PE for 30 min at 4 C. After incubation, the cells were
washed with FACS buffer and ﬁnally suspended in 500 lL
FACS buffer. Harvested cells were injected using a BD
FACSCalibur, USA and data were analyzed using BD
CellQuest software. Stained cells with ﬂuorescent-labeled
antibody exhibiting a higher ﬂuorescence intensity value than
exhibited by unstained control cells were considered positive
[30].
2.7. In vivo experiments investigating E. purpurea effect on
murine splenic DCs
2.7.1. Experimental animals
Male mice were purchased from the animal house of Geiza
Institute of Ophthalmology, Cairo, Egypt. Animal care and
experiments were conducted in accordance with institutional
guidelines and with the approval of the Research Ethics
Committee of Tanta Faculty of Pharmacy. All mice were
6–8 weeks old with an average weight between 20 and 25 g.
Mice were maintained on normal balanced diet and housed
in wire cages for one week under identical environmental con-
ditions for adaptation.
2.7.2. Experimental design
Mice were randomly divided into three major groups (n= 10)
according to the received treatment: Group A, B and C.
2.7.2.1. Group A. This group involved 10 mice representing
control normal, which received PBS orally daily for 5 consec-
utive days.
2.7.2.2. Group B. This group involved 10 mice representing E.
purpurea treated group. Each mouse was given E. purpurea at a
dose of 30 mg/kg/day, suspended in 1.0 mL of PBS and gav-
aged to each animal for 5 consecutive days [1].
2.7.2.3. Group C. This group involved 10 mice representing E.
purpurea+TNF-a treated group. Each mouse was given E.
purpurea as in group B, and then the animal was injected with
TNF-a at a dose of 5 lg/kg, i.p. one hour after the last dose of
E. purpurea [12].
2.8. Isolation of spleen cells
Spleen cell suspension was prepared according to Nakano
et al. [17]. Freshly acquired spleens were immediately pushed
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rod. The cells were resuspended in PBS, then cell suspensions
were centrifuged at 250 g for 10 min at 8 C and supernatants
were discarded. Then, 100 lL of cell suspension was taken and
incubated for 20 min in BD FACS lysing solution for red
blood cell lysis. The cells were rinsed twice in FACS buffer
by centrifugation at 400 g for 10 min at room temperature.
2.9. Flow cytometry of murine splenic DCs
The spleen cells were stained with 10 lL anti-CD83-FITC and
10 lL anti-CD11c-PE. Following 30 min of incubation at 4 C,
the cells were washed twice in FACS buffer [30]. The samples
were injected in ﬂow cytometer BD FACSCalibur, USA.
Data were analyzed using BD CellQuest software to deter-
mine the percentage of each of CD11cCD83+ and
CD11c+CD83+ expressing DCs.
2.10. Statistical analysis
All statistical analyses were accomplished by using Microsoft
Ofﬁce Excel 2007. Differences between groups were statisti-
cally analyzed using one way analysis of variance (ANOVA).
The results were expressed as mean ± standard error (SE). P
values less than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Generation of DCs from PBMCs
PBMCs were cultured in DMEM medium (day 0), allowed to
transform to immature DCs (day 7), which were then differen-
tiated into mature DCs in the presence of TNF-a (day 9)
(Fig. 1).Figure 1 Morphological changes during generation and differ-
entiation of control untreated DCs (40·). (A): Day 0: adherent
monocytes. (B): Day 7: immature DCs. (C): Day 9: mature DCs.
Figure 2 Echinacea purpurea effect on DCs morphology on day 9 (100
treatment). (B): DCs in E. purpurea treated culture, there were no ob
control.3.2. Changes in cell morphology
Microscopically, DCs in various groups reached nearly full
growth on day 7 and completely covered the culture plates
on day 9, where local cell clusters were noted. On day 9,
DCs appeared to be loosely adherent and have branched pro-
jections (Fig. 2A). All culture groups treated with E. purpurea
showed no notable changes in the morphology of DCs com-
pared with control untreated cultures (Fig. 2B).
3.3. Phenotypic characterization of DCs and effect of E.
purpurea
The surface expression of the important DC maturation mar-
ker CD83 was assessed by ﬂow cytometry. The percentage of
DCs that expressed CD83 was 27.25 ± 0.76% in the control
culture of group A, 25.33 ± 0.88% in culture of group B,
31.66 ± 2.19% in culture of group C, 30.66 ± 2.73% in
culture of group D and 17 ± 2.52% in culture of group E
(Fig. 3A and B).
E. purpurea added on day 0 (group E) signiﬁcantly
decreased the expression of CD83 compared to other groups
(Fig. 3B). The CD83 expression was 27.25% in control group
A, and decreased to 17% in E. purpurea treated group E, with
a percent decreased of about 62.4%.
Group B (E. purpurea on day 7 with no TNF-a) and group
D (E. purpurea on day 7 + TNF-a on day 8) showed an
insigniﬁcant change in expression of CD83 compared to con-
trol group A. Group C (TNF-a on day 7 + E. purpurea on
day 8) exhibited the greatest increase in CD83 (31.66%)
although it was insigniﬁcant compared to control culture
group A (Fig. 3B).
3.4. In vivo study
In vivo experiment was conducted to investigate whether treat-
ment of mice with E. purpurea extract has immunomodulatory
effect on murine splenic DCs. We analyzed CD11c-CD83+
and CD11c+CD83+ splenic DCs in E. purpurea-treated mice
by ﬂow cytometry (Fig. 4).
The percentage of each of CD11cCD83+ and
CD11c+CD83+ expressing DCs was determined by ﬂow
cytometry. The percentage of CD11cCD83+ DCs was
38.75 ± 2.73% in the control group A, 38.00 ± 5.19% in
group B and 36.66 ± 3.78% in group C. The percentage of
CD11c+CD83+ DCs was 28.00 ± 3.43% in the control group·). (A): DCs nucleated with branched projections (control without
servable changes in all E. purpurea treated groups compared with
Figure 3 Effect of E. purpurea on CD83 expression in various
cell cultures. (A): Flow cytometry showing the expression of
CD83. Monocyte-derived DCs were generated in presence or
absence of E. purpurea. (Group A) control group; (Group B) E.
purpurea (500 lg/ml) on day 7; (Group C) TNF-a (10 ng/ml) on
day 7 + E. purpurea (500 lg/ml) on day 8; (Group D) E. purpurea
(500 lg/ml) on day 7 + TNF-a (10 ng/ml) on day 8; (Group E) E.
purpurea (500 lg/ml) on day 0 + TNF-a (10 ng/ml) on day 7. (B):
Percentage of DCs expressing CD83 in different groups.
Expression of CD83 cell marker is measured by BD
FACSCalibur. Each value is the mean of 3 experiments ± SE.
*P< 0.05.
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(Fig. 5).
No changes in expression of the accessory molecules were
observed in splenic cells obtained from different animal
groups. E. purpurea-treated mice did not produce any signiﬁ-
cant change in phenotypic analysis of splenic DCs (group B
and group C). Furthermore, the injection of stimulation agent
TNF-a into mice of group C had no effect on the above-
mentioned markers (Fig. 5).
4. Discussion
Dendritic cells (DCs) are professional antigen presenting cells
(APCs) that act at the interface of the innate and adaptivebranches of the immune system. DCs provoke and control
immunity against pathogens and tolerance against self-
antigens and commensal microorganisms [27].
Delivery of adjuvant to DCs may be a promising strategy to
treat autoimmune disorders. But, to produce immunity rather
than tolerance, it is crucial to provide the DCs with an activa-
tion signal [5]. Although a limited number of surface molecules
are preferentially expressed by DCs, high-density CD83
expression is serving as an excellent marker for DC character-
ization [21].
In the present study, PBMCs were cultured and allowed to
generate DCs, which became mature after addition of TNF-a
to the culture. Mature DCs were identiﬁed by microscopical
examination and ﬂow cytometry to detect the expression of
the cell speciﬁc marker CD83.
DCs undergo several changes during maturation including
morphological changes, loss of endocytic and phagocytic
receptors, chemokine secretion, upregulation of costimulatory
molecules, translocation of MHC–II biomarkers to the cell
surface and cytokine secretion [31]. Ultimately these changes
prepare DCs to interact successfully with T cells in the context
of antigen. Activation of the antigen-speciﬁc T cell results in
clonal expansion and differentiation, leading to adaptive
immunity [19].
E. purpurea has been shown to have immunostimulatory
effects on monocytes, macrophages, natural killer cells and T
cells in vitro [9], but few studies have attempted to elucidate
the immunomodulatory effect of E. purpurea on DCs.
In our work, we set out to deﬁne morphological variations
and CD83 phenotypic analysis of DCs after exposure of
cultured peripheral blood monocytes to E. purpurea extract
at different time intervals. In addition, we carried out
phenotypic analysis of splenic DCs obtained from mice treated
with E. purpurea daily for 5 days.
Our results showed that addition of 0.5% of 500 lg/mL E.
purpurea ethanolic extract on day 0 of culture (group E) pro-
duced a signiﬁcant reduction of the expression of immunosup-
pressant cell marker CD83 by 62.4% in cultured DCs when
examined on day 9 compared to control cultures. These results
were conﬁrmed by the work of Wang et al. [32], who reported
that treatment of cultured DCs with E. purpurea extracts at
500 lg/mL greatly decreased the expression of CD83 by 61%
in comparison with negative control DCs.
Because the addition of alcoholic extract of E. purpurea on
day 0 to PBMC cultures decreased the expression of CD83
analyzed on day 9, we thought to analyze the expression of this
molecule at multiple time days. Our results showed that the
expression of CD83 was not signiﬁcantly changed following
treatment of generated DCs with E. purpurea extract added
on day 7 or day 8 either in the presence or absence of
TNF-a (group B, C and D). We inferred that the timing of
addition of E. purpurea extract is critical. We suggest that
E. purpurea extract impacts on DC precursors not on differen-
tiated DCs. This observation is important since this extract can
be used as an immunomodulator, which marked with reduced
expression of CD83 in group E.
Depending on phenotypic and functional states, DCs may
promote immunogenic or tolerogenic responses. Although var-
ious Toll-like receptors, such as TLR3, TLR4, TLR5, TLR7
and TLR8, induce immune activation, others can silence
immune responses through tolerance induction in DCs.
TLR2 activation induces IL-10 production, inhibits
Figure 4 Flow cytometry of cellular markers CD83 and CD11c of murine splenic DCs obtained from all animal groups. Mice of each
group (n = 10) were treated with E. purpurea with or without TNF-a, then splenocytes were analyzed by ﬂow cytometry. T cells and B
cells (CD83) were gated out. Major CD11cCD83+ and CD11c+CD83+ populations are circled. Total CD11cCD83+ cells are gated
by R1, whereas CD11c+CD83+ population is gated by R2. SSC-Height is referred to side scattered pulse height. FSC-Height is referred to





Figure 5 Effect of E. purpurea on the percentage of
CD11cCD83+ and CD11c+CD83+ murine splenic DCs. E.
purpurea was administered orally, whereas TNF-a was given i.p.
n= 10 for each group. Expression of CD11c and CD83 cell
marker was measured by BD FACSCalibur. Each value is the
mean ± SE.
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[13].
Despite the immunogenic ability of DCs in raising immune
responses, which has been attributed to only role in theimmune system, they have also been ascribed opposite roles
in tolerance induction and silencing of immune responses.
DCs play a critical role in the induction of different subsets
of T cells, such as Th1, Th2, Th17 and regulatory T cells
(Tregs) [18].
The source material for experimental studies is usually an
aqueous or ethanol extract of whole, aerial parts or roots of
the dried plant of E. purpurea. The chemical compositions of
the known marker compounds, such as caffeic acid, alky-
lamides and polysaccharides differ substantially between such
preparations [3]. Polysaccharides are typically present at the
highest concentration in aqueous or fresh pressed juice extracts
while alkylamides are more likely to be major constituents in
ethanolic extracts [22]. The present data demonstrated that
the effect of E. purpurea was more apparent on monocytes
rather than fully cultured DCs, whereby this effect might be
contributed by the alkylamide content of E. purpurea alcoholic
extract.E. purpurea drug is indicated for prevention and treat-
ment of common cold and inﬂuenza. Also, it is prescribed as
prophylactic therapy in cases of increased susceptibility to
infections, inﬂammatory skin diseases and recurrent vaginal
candidiasis. Its bioavailability study revealed that following
oral consumption of 675 mg/70 kg of E. purpurea prepared
from dried ethanolic extract, alkylamides appeared in plasma
after 20 min and reached a maximum concentration of
336 ± 131 ng/mL in human plasma, which demonstrates that
alkylamides are bioavailable [15].
In our study, in vivo experiments were performed to com-
pare E. purpurea effect on murine splenic DCs to its effect
Immunomodulatory effect of Echinacea purpurea on dendritic cells 191in vitro. We examined the effect of E. purpurea on different
subsets of splenic DCs in mice through phenotypic analysis.
In accordance with the results obtained in vitro, the in vivo
experiment indicated that oral treatment of mice with E. pur-
purea extract, with or without TNF-a, daily for 5 days pro-
duced no signiﬁcant effect on the subsets of splenic DCs
CD11cCD83+ and CD11c+CD83+ regarding the pheno-
typic analysis. Because we did not study E. purpurea extract
effect on DC precursors in vivo, we could not exclude the pos-
sibility of its effect on PBMCs in vivo. This possibility requires
further study.
In conclusion, our results imply that the immunomodula-
tory mechanisms of E. purpurea affect generation fate of
DCs rather than differentiation stages. The in vivo study
employing murine splenic DCs conﬁrmed those observed
in vitro. It would be worthwhile to investigate the response
of DCs to isolated E. purpurea constituents separately, such
as alkylamides and polysaccharides.References
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